- Home
- / Pharmosa Biopharm
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pharmosa Biopharm financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$61
2024-10-29
Market Capitalization
NT$7.8 B
2024-10-29
Revenue
NT$67.3 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 314.5M | 167.6M | 67.3M | ||||
| Cost of goods sold | 14.9M | 22.8M | |||||
| Gross profit | 296.0K | 4.0M | 2.9M | 232.0K | 320.3M | 153.9M | 44.5M |
| Gross profit margin, % | 101.8% | 91.8% | 66.2% | ||||
| Operating expense total | 129.3M | 176.8M | 247.3M | 258.8M | 294.0M | 345.5M | 415.9M |
| Depreciation and amortization | 9.8M | 10.6M | 11.8M | 12.7M | 23.3M | 25.8M | 31.5M |
| EBITDA | (130.4M) | (168.2M) | (243.8M) | (254.7M) | 31.8M | (189.7M) | (372.3M) |
| EBITDA margin, % | 10.1% | -113.2% | -553.4% | ||||
| EBIT | (140.2M) | (178.8M) | (255.6M) | (267.4M) | 8.5M | (215.6M) | (403.7M) |
| EBIT margin, % | 2.7% | -128.7% | -600.2% | ||||
| Interest income | 30.0K | 39.0K | 100.0K | 500.0K | 9.5M | 32.1M | 29.9M |
| Interest expense | 2.9M | 3.9M | 1.2M | 649.0K | 2.9M | 2.4M | 2.1M |
| Pre tax profit | (129.6M) | (181.7M) | (256.5M) | (266.5M) | 8.5M | (166.7M) | (383.8M) |
| Net Income | (129.6M) | (181.7M) | (256.5M) | (266.5M) | 8.5M | (166.7M) | (383.8M) |